-+ 0.00%
-+ 0.00%
-+ 0.00%

MAIA BIOTECHNOLOGY DOSES FIRST U.S. PATIENT IN ONGOING PHASE 2 NON-SMALL CELL LUNG CANCER CLINICAL TRIAL

路透·09/16/2026 12:15:00

登录查看新闻详情